Fracture Risk of Sodium-Glucose Cotransporter-2 Inhibitors in Chronic Kidney Disease.

ABSTRACT:

Background and objectives

Sodium-glucose cotransporter-2 (SGLT2) inhibitors have been associated with a higher risk of skeletal fractures in some randomized, placebo-controlled trials. Secondary hyperparathyroidism and increased bone turnover (also common in CKD) may contribute to the observed fracture risk. We aimed to determine if SGLT2 inhibitor use associates with a higher risk of fractures compared with dipeptidyl peptidase-4 (DPP-4) inhibitors, which have no known association with fracture risk. We hypothesized that this risk, if present, would be greatest in patients with lower eGFR.

Design, setting, participants, & measurements

We conducted a population-based cohort study in Ontario, Canada between 2015 and 2019 using linked provincial administrative data to compare

SUBMITTER: Cowan A 

PROVIDER: S-EPMC9269654 | biostudies-literature | 2022 Jun

REPOSITORIES: biostudies-literature